7/23/2013

Rosiglitazone did not appear to increase the risk of major cardiac events and death in diabetes patients with coronary artery disease compared with patients not taking a thiazolidinedione-based drug, according to an analysis in the journal Circulation. Researchers also found a lower incidence of the composite of death, myocardial infarction and stroke in patients taking rosiglitazone.

Related Summaries